Mode
Text Size
Log in / Sign up
N/A N=30

Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke

Stroke

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jul 2015
Primary outcome: Primary: Oxygen Consumption During Walking — 11.25; 4.46 ml/kg/min

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Treadmill walking (Behavioral); Magnetic resonance spectroscopy (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jul 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Oxygen Consumption During Walking
11.25; 4.46
SECONDARY
Muscle Mechanical Energy Expenditure
5.66; 3.61
SECONDARY
Magnetic Resonance Spectroscopy of Muscle Metabolic Properties
43.22; 35.39

Summary

Of the ~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. This increased cost likely limits the amount of walking performed, which further reduces functional capacity, thus contributing to long-term spiral of disability and decreased quality of life in these persons. In addition to increased metabolic cost, increased estimates of mechanical work are also characteristic of hemiparetic walking 2,29. Interestingly, although estimates of mechanical work reflect work done by locomotor muscles, little is known about the impact that peripheral muscle properties have on estimates of mechanical work. Furthermore, questions concerning how these properties relate to the increased metabolic cost of walking remain unanswered. The short-term objective and purpose of the proposed research is to determine the extent to which peripheral muscle characteristics, as well as estimates of muscle mechanical energy expenditure (MMEE), relate to the metabolic cost of walking post-stroke.

Eligibility Criteria

Inclusion Criteria

  • age 18-80;
  • stroke within past 6 months - 5 years;
  • residual paresis in the lower extremity (LE) (Fugl-Meyer motor score 200 mmHg and diastolic >110 mmHg at rest;
  • Previous or current enrollment in a clinical trial to enhance motor recovery;
  • Presence of non-magnetic resonance (MR) compatible implants or devices, pregnancy or severe claustrophobia.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00721357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search